Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 3

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 3
---
 current liabilities

    59,684

    43,942

    Operating lease liabilities, non-current

    44,570

    47,555

    Deferred revenue, non-current

    4,704

    4,750

    Other non-current liabilities

    829

    —

    Total liabilities

    109,787

    96,247

    Commitments and contingencies (Note 7)

    Stockholders’ equity:

    Preferred stock, $0.001 par; 10,000 shares authorized, no shares   issued or outstanding at December 31, 2024 or 2023

    —

    —

    Common stock and paid-in capital, $0.001 par; 200,000 shares authorized,   92,926 shares issued and outstanding at December 31, 2024;  68,175 shares issued and outstanding at December 31, 2023

    2,275,952

    1,191,831

    Accumulated other comprehensive income (loss)

    963

    977

    Accumulated deficit

    (952,110
    )

    (653,702
    )

    Total stockholders’ equity

    1,324,805

    539,106

    Total liabilities and stockholders’ equity
     
    $
    1,434,592

    $
    635,353

See the accompanying notes to these consolidated financial statements. 

F-4

CRINETICS PHARMACEUTICALS, INC.

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data) 

    Year ended December 31,

    2024

    2023

    2022

    Revenues
     
    $
    1,039

    $
    4,013

    $
    4,737

    Operating expenses:

    Research and development

    240,156

    168,527

    130,225

    General and administrative

    99,737

    58,094

    42,394

    Total operating expenses

    339,893

    226,621

    172,619

    Loss from operations

    (338,854
    )

    (222,608
    )

    (167,882
    )

    Other income (